Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C

The Journal of Infectious Diseases
Chihiro MorishimaHepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group

Abstract

Pretreatment hepatitis C virus (HCV)-specific lymphoproliferative (LP) responses, neutralizing antibody (NA) responses, intrahepatic cytotoxic T lymphocyte (CTL) responses, and HCV quasi-species (QS) diversity and complexity were examined in patients with advanced hepatic fibrosis (Ishak fibrosis score of > or = 3) and prior nonresponse to interferon (IFN)- alpha therapy who were enrolled in the initial phase of the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis Trial. Positive baseline HCV E1- and/or E2-specific NA responses (P = .01) and higher baseline HCV QS diversity (P = .01) were more commonly found in patients who did not become sustained virologic responders (SVRs) at week 72 (W72) than they were in those who did. No patients with positive results for both the LP and NA assays achieved a sustained virologic response. Multiple logistic regression analysis revealed that, when the presence of cirrhosis, prior ribavirin therapy, genotype 1 infection, log serum HCV RNA level, and receipt of >80% of the prescribed medication were controlled for, a sustained virologic response (W72) was negatively correlated with positive baseline LP assay results (P = .02) and with 1 or more positive assays (LP, NA, or CTL) (P =...Continue Reading

Citations

Feb 7, 2012·Enfermedades infecciosas y microbiología clínica·Verónica Saludes MontoroElisa Martró Català
Dec 21, 2007·Journal of Virology·Keith MeyerRanjit Ray
Jun 13, 2012·Microbiology and Molecular Biology Reviews : MMBR·Esteban DomingoCelia Perales
May 9, 2008·PloS One·Nathan A CannonUNKNOWN Virahep-C Study Group
May 10, 2012·PLoS Pathogens·Rebecca R GrayOliver G Pybus
Sep 15, 2011·Immunotherapy·Aarthi Chary, Mark Holodniy
Jun 4, 2015·Emerging Microbes & Infections·Adrian EgliMichael Houghton
Sep 29, 2011·Virus Research·Samuel OjosnegrosEsteban Domingo
Jun 25, 2009·Gastroenterology·Arthur Y Kim, Raymond T Chung
Oct 9, 2007·Gastroenterology·Massimo PilliUNKNOWN DITTO-HCV Study Group
Mar 14, 2007·Virus Research·Esteban Domingo, Jordi Gomez
Dec 5, 2008·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Hiroyoshi DoiMichio Imawari
Dec 29, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jason T BlackardKenneth E Sherman
May 11, 2012·Journal of Viral Hepatitis·C MorishimaUNKNOWN HALT-C Trial Group
Nov 26, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Xiaofeng FanAdrian M Di Bisceglie
Oct 22, 2013·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Alejandro Escobar-GutiérrezMayra Cruz-Rivera
Oct 2, 2012·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Verónica SaludesElisa Martró
Apr 26, 2017·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·José M BenitoNorma Rallón
Aug 24, 2006·Journal of Medical Virology·Nicasio ManciniRoberto Burioni
May 26, 2021·Clinics in Perinatology·Rachel L Epstein, Claudia Espinosa
Dec 5, 2006·Current Opinion in Rheumatology

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.